IL148408A0 - Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins - Google Patents

Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

Info

Publication number
IL148408A0
IL148408A0 IL14840800A IL14840800A IL148408A0 IL 148408 A0 IL148408 A0 IL 148408A0 IL 14840800 A IL14840800 A IL 14840800A IL 14840800 A IL14840800 A IL 14840800A IL 148408 A0 IL148408 A0 IL 148408A0
Authority
IL
Israel
Prior art keywords
formulations
parenteral use
estramustine phosphate
sulfoalkyl ether
ether cyclodextrins
Prior art date
Application number
IL14840800A
Other languages
English (en)
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of IL148408A0 publication Critical patent/IL148408A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14840800A 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins IL148408A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921958.6A GB9921958D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
PCT/EP2000/007680 WO2001019339A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

Publications (1)

Publication Number Publication Date
IL148408A0 true IL148408A0 (en) 2002-09-12

Family

ID=10861068

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14840800A IL148408A0 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

Country Status (19)

Country Link
US (1) US6730664B1 (xx)
EP (1) EP1212041A1 (xx)
JP (1) JP2003509356A (xx)
KR (1) KR20020059401A (xx)
CN (1) CN1374857A (xx)
AU (1) AU777684B2 (xx)
BR (1) BR0014062A (xx)
CA (1) CA2385065A1 (xx)
CZ (1) CZ2002944A3 (xx)
EA (1) EA003936B1 (xx)
GB (1) GB9921958D0 (xx)
HU (1) HUP0300185A3 (xx)
IL (1) IL148408A0 (xx)
MX (1) MXPA02002855A (xx)
NO (1) NO20021270L (xx)
PL (1) PL356026A1 (xx)
SK (1) SK3462002A3 (xx)
WO (1) WO2001019339A1 (xx)
ZA (1) ZA200201744B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
CA2631014C (en) * 2005-11-28 2015-04-28 Vernon D. Rowe Compositions useful for reducing nephrotoxicity and methods of use thereof
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
WO2024074600A1 (en) * 2022-10-05 2024-04-11 Institut Gustave Roussy An oral liquid composition of vinorelbine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523035A (en) * 1976-03-10 1978-08-31 Leo Ab Derivatives of estradiol - 17 - dihydrogen phosphates
JPS59108800A (ja) 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) * 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
EA200200370A1 (ru) 2002-10-31
GB9921958D0 (en) 1999-11-17
EA003936B1 (ru) 2003-10-30
NO20021270D0 (no) 2002-03-14
JP2003509356A (ja) 2003-03-11
KR20020059401A (ko) 2002-07-12
EP1212041A1 (en) 2002-06-12
SK3462002A3 (en) 2002-08-06
MXPA02002855A (es) 2003-07-21
AU6993900A (en) 2001-04-17
HUP0300185A2 (en) 2003-05-28
CN1374857A (zh) 2002-10-16
BR0014062A (pt) 2002-12-31
PL356026A1 (en) 2004-05-31
CA2385065A1 (en) 2001-03-22
US6730664B1 (en) 2004-05-04
AU777684B2 (en) 2004-10-28
CZ2002944A3 (cs) 2002-08-14
HUP0300185A3 (en) 2007-02-28
WO2001019339A1 (en) 2001-03-22
ZA200201744B (en) 2004-01-28
NO20021270L (no) 2002-03-14

Similar Documents

Publication Publication Date Title
HUP0202477A3 (en) Use of phthalazine derivatives
PL354623A1 (en) Manufacture of polyglutamate-therapeutic agent conjugates
HUP0202759A3 (en) Medium for the protein-free and serum-free cultivation of cells
AU6406999A (en) Devices for investing within ligaments for retracting and reinforcing the same
IL137595A0 (en) Technique for creating audience-specific views of documents
AU4496800A (en) Laminin 2 and methods for its use
EP1230456A4 (en) CELLULOSIC ETHERS AND PROCESS FOR THE PREPARATION THEREOF
AU4239800A (en) Low noise in-building distribution network for wireless signals
AU2500600A (en) Antisense modulation of integrin beta 3 expression
AU8967998A (en) Antibiotic-ligand conjugates and methods of use thereof
IL148656A0 (en) Differentially expanding stent and methods of use
AU6157899A (en) Catheter flush solution and method for its use
IL148408A0 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
AU7792900A (en) Distribution of certifiers
AU3436701A (en) Master frequency generator
AU7853700A (en) Foams and compositions containing these foams
AU4678400A (en) Laminin 8 and methods for its use
PL334333A1 (en) Method of obtaining cyclodextrin
IL147745A0 (en) Formulations for parenteral use of estramustine phosphate and albumin
IL148409A0 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
AU6230499A (en) Method for preparing 2-chloropropionaldehyde and use of the same
GB9918779D0 (en) Formulations for parenteral use of estramustine phosphate and albumin
AU2627999A (en) Novel derivatives of cyclodextrins
AU6764700A (en) Master frequency generator
AU7609200A (en) Event based system for use within the creation and implementation of educationalsimulations